The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.
 
Frederique Madeleine Penault-Llorca
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo; BAYER; BeiGene; BMS; Eisai Europe; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Illumina; Janssen; Lilly; Lilly (Inst); MSD; MSD/AstraZeneca; Myriad genetics; NanoString Technologies; Novartis; Pfizer; Roche; Roche (Inst); SERVIER
Research Funding - Bayer (Inst); MSD (Inst); Myriad Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer (Inst); Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Lilly; MSD (Inst); Novartis; Pfizer; Roche (Inst)
 
Amelie Lusque
No Relationships to Disclose
 
Thomas Filleron
Consulting or Advisory Role - Cellectis (Inst)
Research Funding - Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst)
Other Relationship - Janssen; Roche (Inst)
 
Kevin Tran
No Relationships to Disclose
 
Lili Du
No Relationships to Disclose
 
Frederick Baehner
Employment - Exact Sciences
Leadership - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
 
Florence Dalenc
Honoraria - AstraZeneca (Inst); Gilead Sciences (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer
 
Magali Lacroix-Triki
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genomic Health; MSD Oncology; Myriad Genetics; Roche Diagnostics Solutions
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Roche Diagnostics Solutions
 
Thomas Bachelot
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Pfizer (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; pfizer; Roche
 
Fabrice Andre
Consulting or Advisory Role - AstraZeneca (Inst); Boston Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Lilly; Lilly (Inst); N-Power Medicine (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); ROCHE (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Guardant Health (Inst); Lilly (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Pascal Boucher
No Relationships to Disclose
 
Jerome Lemonnier
No Relationships to Disclose
 
W. Fraser Fraser Symmans
Stock and Other Ownership Interests - Delphi Diagnostics; Eiger BioPharmaceuticals; ISIS Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Merck
Patents, Royalties, Other Intellectual Property - Intellectual property; Intellectual Property (expired)
(OPTIONAL) Uncompensated Relationships - Delphi Diagnostics